[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Caribou Biosciences Inc (CRBU)

Caribou Biosciences Inc (CRBU)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 212,247
  • Shares Outstanding, K 99,181
  • Annual Sales, $ 11,160 K
  • Annual Income, $ -148,130 K
  • EBIT $ -132 M
  • EBITDA $ -129 M
  • 60-Month Beta 2.27
  • Price/Sales 19.02
  • Price/Cash Flow N/A
  • Price/Book 2.07

Options Overview Details

View History
  • Implied Volatility 147.48% (-4.93%)
  • Historical Volatility 56.48%
  • IV Percentile 26%
  • IV Rank 14.66%
  • IV High 471.92% on 05/21/25
  • IV Low 91.77% on 07/18/25
  • Expected Move (DTE 31) 0.55 (25.82%)
  • Put/Call Vol Ratio 0.15
  • Today's Volume 84
  • Volume Avg (30-Day) 470
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 9,246
  • Open Int (30-Day) 7,809
  • Expected Range 1.59 to 2.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.33
  • Number of Estimates 4
  • High Estimate $-0.29
  • Low Estimate $-0.38
  • Prior Year $-0.35
  • Growth Rate Est. (year over year) +5.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.83 +16.94%
on 05/01/26
2.39 -10.46%
on 04/23/26
-0.06 (-2.73%)
since 04/15/26
3-Month
1.51 +41.72%
on 02/17/26
2.39 -10.46%
on 04/23/26
+0.56 (+35.44%)
since 02/13/26
52-Week
0.82 +160.98%
on 05/16/25
3.54 -39.55%
on 11/03/25
+1.30 (+154.79%)
since 05/15/25

Most Recent Stories

More News
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference

BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences , Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou’s...

CRBU : 2.14 (unch)
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences , Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts...

CRBU : 2.14 (unch)
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update

-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- --...

CRBU : 2.14 (unch)
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference

BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences , Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,...

CRBU : 2.14 (unch)
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

-- RMAT granted based on promising initial clinical data, including previously disclosed recommended dose for expansion data of 92% ORR, 75% ≥CR rate, 91% MRD negativity in the 12-patient, BCMA-naïve...

CRBU : 2.14 (unch)
Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences , Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results...

CRBU : 2.14 (unch)
Caribou Biosciences to Participate in Upcoming Investor Conferences

BERKELEY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced management will...

CRBU : 2.14 (unch)
Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®

Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programs Vispa-cel (CB-010) ANTLER phase 1 translational and clinical...

CRBU : 2.14 (unch)
Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025

KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting ...

CRBU : 2.14 (unch)
Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Vispa-cel (CB-010) ANTLER phase 1 data demonstrate efficacy and durability on par with autologous CAR-T cell therapy and safety allows for outpatient use, highlighting its potential as a best-in-class...

CRBU : 2.14 (unch)

Business Summary

Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 2.29
2nd Resistance Point 2.24
1st Resistance Point 2.19
Last Price 2.14
1st Support Level 2.09
2nd Support Level 2.04
3rd Support Level 1.99

See More

52-Week High 3.54
Fibonacci 61.8% 2.50
Fibonacci 50% 2.18
Last Price 2.14
Fibonacci 38.2% 1.86
52-Week Low 0.82

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.